Another one has shown that p53 expression could predict the complete response to chemotherapy in patients with HER2-positive breast cancer treated with sequential cycles of doxorubicin and cyclophosphamide followed by trastuzumab and paclitaxel [352]. This evidence concerns the gene ERBB2 and breast carcinoma.